🚀
Enjoy a 7-Day Free Trial Thru May 06, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
WuXi Biologics (Cayman) Inc (FRA:1FW2)
News
WuXi Biologics (Cayman) Inc - Registered Shs Unita
FRA
:1FW2 (China) Â
Registered Shs Unitary 144A/Reg S
€ 1.64
(+8.75%)
Apr 26
P/E:
16.01
P/B:
1.30
Market Cap:
€ 6.68B
($ 7.15B)
Enterprise V:
€ 5.82B
($ 6.23B)
Volume:
2.00K
Avg Vol (2M):
2.75K
Warning! GuruFocus detected 1 Severe warning sign with 1FW2.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
2.00K
Market Cap €:
6.68B
Market Cap $:
7.15B
PE Ratio:
16.01
Avg Vol (2M):
2.75K
Enterprise Value €:
5.82B
Enterprise Value $:
6.23B
PB Ratio:
1.30
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
WuXi Biologics (Cayman) Inc (FRA:1FW2) Stock News, Headlines & Updates
WuXi Biologics (Cayman) Inc Stock News from GuruFocus
Total 109
1
2
3
Mar 26, 2024
WuXi Biologics Reports Solid 2023 Annual Results
PRNewswire
•
9:00am
Mar 22, 2024
WuXi Biologics Named to CDP 'A List' for Water Security
PRNewswire
•
5:00am
Mar 05, 2024
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
PRNewswire
•
8:00am
Feb 21, 2024
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
PRNewswire
•
5:00am
Feb 15, 2024
WuXi Biologics (Cayman) Inc at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
7:24am
Half Year 2021 WuXi Biologics (Cayman) Inc Earnings Call Transcript
GuruFocus Research
•
7:24am
Jan 25, 2024
WuXi Biologics Launches WuXia ADCC PLUSâ„¢ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
PRNewswire
•
7:00pm
Jan 17, 2024
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBodyâ„¢
PRNewswire
•
7:00pm
Jan 10, 2024
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
PRNewswire
•
11:00am
Jan 08, 2024
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
PRNewswire
•
4:00am
Dec 12, 2023
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
PRNewswire
•
4:00am
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
PRNewswire
•
3:00am
Dec 08, 2023
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
PRNewswire
•
4:00am
Nov 22, 2023
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
PRNewswire
•
12:00am
Nov 14, 2023
WuXi Biologics Receives AAA MSCI ESG Rating
PRNewswire
•
12:01am
Oct 17, 2023
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUIâ„¢ for Cost-Effective Commercial Manufacturing and Desirable Product Quality
PRNewswire
•
8:00pm
Oct 02, 2023
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
PRNewswire
•
8:00pm
Aug 23, 2023
WuXi Biologics Reports Solid 2023 Interim Results
PRNewswire
•
9:00am
Aug 11, 2023
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
PRNewswire
•
8:00pm
Jul 26, 2021
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
PRNewswire
•
6:02am
Jun 10, 2021
WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates
PRNewswire
•
8:00pm
May 27, 2021
WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
PRNewswire
•
8:00pm
May 14, 2021
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
PRNewswire
•
8:00pm
Feb 25, 2021
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
PRNewswire
•
7:04pm
Feb 09, 2021
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
PRNewswire
•
7:01pm
Dec 28, 2020
WuXi Biologics Receives GMP Certification from Brazil's ANVISA
PRNewswire
•
7:00am
Dec 21, 2020
WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer
PRNewswire
•
7:03am
Dec 02, 2020
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation
PRNewswire
•
7:03am
Nov 20, 2020
WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou
PRNewswire
•
3:00am
Oct 29, 2020
WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa
PRNewswire
•
7:04am
Oct 10, 2020
Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines
PRNewswire
•
11:00am
Aug 17, 2020
WuXi Biologics Records Excellent Interim Results
PRNewswire
•
11:02am
Aug 06, 2020
WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer
PRNewswire
•
7:03am
Aug 04, 2020
WuXi Biologics Awarded as "Most Honored Company" by Institutional Investor
PRNewswire
•
7:01am
Jun 19, 2020
Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day
PRNewswire
•
7:00am
Jun 16, 2020
WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing
PRNewswire
•
7:01pm
Jun 09, 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
PRNewswire
•
7:02pm
May 28, 2020
WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories
PRNewswire
•
7:03pm
May 19, 2020
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States
PRNewswire
•
7:02pm
Apr 30, 2020
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBodyâ„¢ Platform
PRNewswire
•
7:02am
Total 109
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news